Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

Carlton D. Dampier, MD, Marilyn J. Telen, MD, Ted Wun, MD, Wally R Smith, MD, R. Clark Brown, MD PhD, Payal Desai, MD, Fuad A El Rassi, MD, Julie Kanter, MD, Beng R. Fuh, MD, Yves D. Pastore, MD, Jennifer A. Rothman, MD, James G. Taylor, MD, David Readett, BM, BS, MRCP, Jay N Lozier, MDPhD, John L. Magnani, PhD, Helen M Thackray, MD, Kathryn L. Hassell, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134803

Published: 2020

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Daniel J. DeAngelo, MD PhD, Harry P. Erba, MD PhD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Gerwin Huls, MD PhD, Jane L. Liesveld, MD, Brenda Cooper, MD, Bhavana Bhatnagar, DO, Geoffrey L. Uy, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Michael B. Armstrong, MD PhD, William E. Fogler, PhD, Mary M Chen, MD PhD, John L. Magnani, PhD, Helen M Thackray, MD, Eric J. Feldman, MD, Anjali S. Advani, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2650.

https://doi.org/10.1182/blood-2019-123816

Published: 2019

Journal Articles

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

Daniel J. DeAngelo, MD, Brian A. Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD PhD, Anjali S. Advani, MD, Paula Marlton, Michael E O'Dwyer, MD, William E Fogler, PhD, Curt D Wolfgang, PhD, John L Magnani, PhD, Helen M Thackray, MD, Pamela S. Becker, MD

Blood (2018) 132 (Supplement 1): 331.

https://doi.org/10.1182/blood-2018-99-114286

Published: 2018

Journal Articles

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

Sylvia S Chien, Jin Dai, PhD, John L Magnani, PhD, Taylor S Sekizaki, William E Fogler, PhD, Helen M Thackray, MD, Kelda Gardner, PA-C, Elihu H. Estey, MD, Pamela S Becker, MD PhD

Blood (2018) 132 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2018-99-119449

Published: 2018

Journal Articles

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Daniel J. DeAngelo, MD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, Anjali S. Advani, MD, Paula Marlton, MBBS, Michael O'Dwyer, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2017) 130 (Supplement 1): 894.

https://doi.org/10.1182/blood.V130.Suppl_1.894.894

Published: 2017

Journal Articles

Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML

William E. Fogler, PhD, Henry Flanner, MS, Curt Wolfgang, PhD, Jeffrey Allen Smith, Helen M. Thackray, MD, John L Magnani, PhD

Blood (2016) 128 (22): 2826.

https://doi.org/10.1182/blood.V128.22.2826.2826

Published: 2016

Journal Articles

A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date

Daniel J. DeAngelo, MD PhD, Jane L. Liesveld, MD, Brian A Jonas, MD PhD, Michael E O'Dwyer, MD, Dale L. Bixby, MD, John L Magnani, PhD, Helen M. Thackray, MD, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 4049.

https://doi.org/10.1182/blood.V128.22.4049.4049

Published: 2016

Journal Articles

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

Dana E. Angelini, MD, Sumana Devata, MD, Angela E. Hawley, Susan A. Blackburn, RN, MBA, Satwinder Grewal, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, William E Parker, Yu-Ling Li, MS, MD, Daniel Durant Myers, DVM, MPH, James B. Froehlich, MD MPH, John L Magnani, PhD, Helen M. Thackray, MD, Thomas W. Wakefield, MD, Suman L. Sood, MD MSCE

Blood (2016) 128 (22): 3826.

https://doi.org/10.1182/blood.V128.22.3826.3826

Published: 2016

Journal Articles

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Sumana Devata, MD, Suman L. Sood, MD, Martina V Hemmer, MA, Henry Flanner, MS, William Kramer, PhD, Christine Nietubicz, Angela Hawley, Dana E Angelini, MD, Daniel Durant Myers, DVM, MPH, Susan Blackburn, James Froehlich, MD, Thomas W. Wakefield, MD, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2015) 126 (23): 1004.

https://doi.org/10.1182/blood.V126.23.1004.1004

Published: 2015

Journal Articles

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

Ted Wun, MD, Marilyn J. Telen, MD, Lakshmanan Krishnamurti, MD, Timothy L. McCavit, MD, Laura M DeCastro, MD, Henry Flanner, ME, Frans A. Kuypers, PhD, Sandra K. Larkin, MS, Seungshin Rhee, MS, John L. Magnani, PhD, Helen M. Thackray, MD

Blood (2014) 124 (21): 2704.

https://doi.org/10.1182/blood.V124.21.2704.2704

Published: 2014

Journal Articles

Safety, Tolerability and Pharmacokinetics of GMI-1070, a Pan-Selectin Inhibitor for Treatment of Vaso-Occlusive Crisis: Single and Multiple Dose Studies in Healthy Volunteers.

Yuli Xie, MS, Rebecca Seufert, RN, John L. Magnani, PhD, William Kramer, PhD, Helen M. Thackray, MD

Blood (2009) 114 (22): 1526.

https://doi.org/10.1182/blood.V114.22.1526.1526

Published: 2009

NARROW

Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia

Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses

E-Selectin Ligand Expression By Leukemic Blasts Is Associated with Prognosis in Patients with AML

GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study

Administration of the Dual E-Selectin/CXCR4 Antagonist, GMI-1359, Results in a Unique Profile of Tumor Mobilization from the Bone Marrow and Facilitation of Chemotherapy in a Murine Model of FLT3 ITD AML

A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date

E-Selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile

Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis

Safety, Tolerability and Pharmacokinetics of GMI-1070, a Pan-Selectin Inhibitor for Treatment of Vaso-Occlusive Crisis: Single and Multiple Dose Studies in Healthy Volunteers.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only